Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–432.
   PubMed Web of Science ®Google Scholar
• Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5:3156.
   PubMed Web of Science ®Google Scholar
• Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23(2):186–199.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Ann Clin Biochem. 2011;48(Pt 4):295–299.
   PubMedGoogle Scholar
• Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res. 2012;72(11):2701–2704.
   PubMed Web of Science ®Google Scholar
• Lutz AM, Willmann JK, Drescher CW, et al. Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology. 2011;259(2):329–345.
   PubMed Web of Science ®Google Scholar
• Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet. 2011;204(10):525–535.
   PubMed Web of Science ®Google Scholar
• Seoung JPY, Rhim C, Kim S. Current possible drug therapies for ovarian cancer. J Cancer Ther. 2014;5(13):1203–1214.
   Google Scholar
• Pinato DJ, Graham J, Gabra H, et al. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev. 2013;39(2):153–160.
   PubMed Web of Science ®Google Scholar
• Barrena Medel NI, Wright JD, Herzog TJ. Targeted therapies in epithelial ovarian cancer. J Oncol. 2010;2010:314326.
   PubMedGoogle Scholar
• Nawaz M, Camussi G, Valadi H, et al. The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nat Rev Urol. 2014;11(12):688–701.
   PubMed Web of Science ®Google Scholar
• Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–383.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659.
   PubMed Web of Science ®Google Scholar
• Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–1476.
   PubMed Web of Science ®Google Scholar
• Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10(5):619–624.
   PubMed Web of Science ®Google Scholar
• Melo SA, Sugimoto H, O’Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–721.
   PubMed Web of Science ®Google Scholar
• Kim DK, Lee J, Kim SR, et al. EVpedia: a community web portal for extracellular vesicles research. Bioinformatics. 2015;31(6):933–939.
   PubMed Web of Science ®Google Scholar
• Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–335.
   PubMed Web of Science ®Google Scholar
• Gomes J, Gomes-Alves P, Carvalho SB, et al. Extracellular vesicles from ovarian carcinoma cells display specific glycosignatures. Biomolecules. 2015;5(3):1741–1761.
   PubMed Web of Science ®Google Scholar
• Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816–826.
   PubMed Web of Science ®Google Scholar
• An T, Qin S, Xu Y, et al. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J Extracell Vesicles. 2015;4:27522.
   PubMed Web of Science ®Google Scholar
• Lin J, Li J, Huang B, et al. Exosomes: novel biomarkers for clinical diagnosis. ScientificWorldJournal. 2015;2015:657086.
   PubMedGoogle Scholar
• Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289.
   PubMed Web of Science ®Google Scholar
• Yanez-Mo M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
   PubMed Web of Science ®Google Scholar
• Nawaz M, Fatima F, Vallabhaneni KC, et al. Extracellular vesicles: evolving factors in stem cell biology. Stem Cells Int. 2016;2016:1073140.
   PubMed Web of Science ®Google Scholar
• Fatima F, Nawaz M. Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy. Chin J Cancer. 2015;34(3):46.
   PubMedGoogle Scholar
• Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883–891.
   PubMed Web of Science ®Google Scholar
• Al-Nedawi K, Meehan B, Kerbel RS, et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009;106(10):3794–3799.
   PubMed Web of Science ®Google Scholar
• Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14(3):195–208.
   PubMed Web of Science ®Google Scholar
• Gobbo J, Marcion G, Cordonnier M, et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. J Natl Cancer Inst. 2016;108:3.
   Google Scholar
• Mitchell PJ, Welton J, Staffurth J, et al. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med. 2009;7:4.
   PubMed Web of Science ®Google Scholar
• Ge Q, Zhou Y, Lu J, et al. miRNA in plasma exosome is stable under different storage conditions. Molecules. 2014;19(2):1568–1575.
   PubMed Web of Science ®Google Scholar
• Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014;29:116–125.
   PubMed Web of Science ®Google Scholar
• Akers JC, Gonda D, Kim R, et al. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113(1):1–11.
   PubMed Web of Science ®Google Scholar
• Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2:20360.
   PubMedGoogle Scholar
• Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990;75(2):263–273.
   PubMed Web of Science ®Google Scholar
• Puls LE, Duniho T, Hunter JE, et al. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol. 1996;61(1):109–112.
   PubMed Web of Science ®Google Scholar
• Enriquez VA, Cleys ER, Da Silveira JC, et al. High LIN28A expressing ovarian cancer cells secrete exosomes that induce invasion and migration in HEK293 cells. Biomed Res Int. 2015;2015:701390.
   PubMedGoogle Scholar
• Vaksman O, Trope C, Davidson B, et al. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis. 2014;35(9):2131–2120.
   PubMed Web of Science ®Google Scholar
• Graves LE, Ariztia EV, Navari JR, et al. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res. 2004;64(19):7045–7049.
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Salomon C, Tapia J, et al. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med. 2014;12:4.
   PubMed Web of Science ®Google Scholar
• Sinha A, Ignatchenko V, Ignatchenko A, et al. In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome. Biochem Biophys Res Commun. 2014;445(4):694–701.
   PubMed Web of Science ®Google Scholar
• Gercel-Taylor C, Atay S, Tullis RH, et al. Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. Anal Biochem. 2012;428(1):44–53.
   PubMed Web of Science ®Google Scholar
• An HJ, Miyamoto S, Lancaster KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006;5(7):1626–1635.
   PubMed Web of Science ®Google Scholar
• de la Fuente A, Alonso-Alconada L, Costa C, et al. M-Trap: exosome-based capture of tumor cells as a new technology in peritoneal metastasis. J Natl Cancer Inst. 2015;107(9). pii: djv184. doi:10.1093/jnci/djv184.
   PubMedGoogle Scholar
• Pospichalova V, Svoboda J, Dave Z, et al. Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer. J Extracell Vesicles. 2015;4:25530.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Yang Y, Zeng Y, et al. A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. Lab Chip. 2016;16(3):489–496.
   Web of Science ®Google Scholar
• Zhang W, Peng P, Kuang Y, et al. Characterization of exosomes derived from ovarian cancer cells and normal ovarian epithelial cells by nanoparticle tracking analysis. Tumour Biol. 2015. doi:10.1007/s13277-015-4105-8
   Google Scholar
• Dolo V, D’Ascenzo S, Violini S, et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis. 1999;17(2):131–140.
   PubMed Web of Science ®Google Scholar
• Ginestra A, La Placa MD, Saladino F, et al. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res. 1998;18(5a):3433–3437.
   PubMed Web of Science ®Google Scholar
• Taylor DD, Lyons KS, Gercel-Taylor C. Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol. 2002;84(3):443–448.
   PubMed Web of Science ®Google Scholar
• Hakulinen J, Junnikkala S, Sorsa T, et al. Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol. 2004;34(9):2620–2629.
   PubMed Web of Science ®Google Scholar
• Runz S, Keller S, Rupp C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol. 2007;107(3):563–571.
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Elkin M, Abboud-Jarrous G, et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res. 2008;49(3):207–210.
   PubMed Web of Science ®Google Scholar
• Keller S, Konig AK, Marme F, et al. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett. 2009;278(1):73–81.
   PubMed Web of Science ®Google Scholar
• Rupp AK, Rupp C, Keller S, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol Oncol. 2011;122(2):437–446.
   PubMed Web of Science ®Google Scholar
• Liang B, Peng P, Chen S, et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteomics. 2013;80c:171–182.
   Web of Science ®Google Scholar
• Clancy JW, Sedgwick A, Rosse C, et al. Regulated delivery of molecular cargo to invasive tumour-derived microvesicles. Nat Commun. 2015;6:6919.
   PubMed Web of Science ®Google Scholar
• Gutwein P, Mechtersheimer S, Riedle S, et al. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J. 2003;17(2):292–294.
   PubMedGoogle Scholar
• Gutwein P, Stoeck A, Riedle S, et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res. 2005;11(7):2492–2501.
   PubMed Web of Science ®Google Scholar
• Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003;362(9387):869–875.
   PubMed Web of Science ®Google Scholar
• Stoeck A, Keller S, Riedle S, et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J. 2006;393(Pt 3):609–618.
   PubMed Web of Science ®Google Scholar
• Baumann P, Cremers N, Kroese F, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005;65(23):10783–10793.
   PubMed Web of Science ®Google Scholar
• Kristiansen G, Denkert C, Schluns K, et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002;161(4):1215–1221.
   PubMed Web of Science ®Google Scholar
• Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004;35(3):255–262.
   PubMed Web of Science ®Google Scholar
• Choi YL, Kim SH, Shin YK, et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol. 2005;97(2):379–386.
   PubMed Web of Science ®Google Scholar
• Li J, Sherman-Baust CA, Tsai-Turton M, et al. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009;9:244.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Agarwal R, Keeney GA, et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol. 2008;109(2):263–269.
   PubMed Web of Science ®Google Scholar
• Choi YL, Kim J, Kwon MJ, et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol. 2007;22(11):1185–1195.
   PubMed Web of Science ®Google Scholar
• Kleinberg L, Holth A, Trope CG, et al. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol. 2008;39(5):747–757.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80.
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.
   PubMed Web of Science ®Google Scholar
• Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430–439.
   PubMed Web of Science ®Google Scholar
• Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284(49):34211–34222.
   PubMed Web of Science ®Google Scholar
• Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151(7):1542–1556.
   PubMed Web of Science ®Google Scholar
• Shimoda M, Principe S, Jackson HW, et al. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat Cell Biol. 2014;16(9):889–901.
   PubMed Web of Science ®Google Scholar
• Lis R, Touboul C, Raynaud CM, et al. Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. Plos One. 2012;7(5):e38340.
   PubMedGoogle Scholar
• Cho JA, Park H, Lim EH, et al. Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol Oncol. 2011;123(2):379–386.
   PubMed Web of Science ®Google Scholar
• Yang Y, Bucan V, Baehre H, et al. Acquisition of new tumor cell properties by MSC-derived exosomes. Int J Oncol. 2015;47(1):244–252.
   PubMed Web of Science ®Google Scholar
• Yang Y, Otte A, Hass R. Human mesenchymal stroma/stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell lines. Stem Cells Dev. 2015;24(10):1205–1222.
   PubMed Web of Science ®Google Scholar
• Iero M, Valenti R, Huber V, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008;15(1):80–88.
   PubMed Web of Science ®Google Scholar
• Rak J. Microparticles in cancer. Semin Thromb Hemost. 2010;36(08):888–906.
   PubMedGoogle Scholar
• Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA: Journal Am Med Assoc. 2002;287(13):1671–1679.
   PubMed Web of Science ®Google Scholar
• Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011;71(15):5346–5356.
   PubMed Web of Science ®Google Scholar
• Yi H, Ye J, Yang XM, et al. High-grade ovarian cancer secreting effective exosomes in tumor angiogenesis. Int J Clin Exp Pathol. 2015;8(5):5062–5070.
   PubMed Web of Science ®Google Scholar
• Dolo V, D’Ascenzo S, Giusti I, et al. Shedding of membrane vesicles by tumor and endothelial cells. Ital J Anat Embryol. 2005;110(2 Suppl 1):127–133.
   PubMedGoogle Scholar
• Taraboletti G, D’Ascenzo S, Giusti I, et al. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia. 2006;8(2):96–103.
   PubMed Web of Science ®Google Scholar
• Lee TH, D’Asti E, Magnus N, et al. Microvesicles as mediators of intercellular communication in cancer–the emerging science of cellular ‘debris’. Semin Immunopathol. 2011;33(5):455–467.
   PubMed Web of Science ®Google Scholar
• Millimaggi D, Mari M, D’Ascenzo S, et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 2007;9(4):349–357.
   PubMed Web of Science ®Google Scholar
• Yi H, Zheng X, Song J, et al. Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis. Int J Clin Exp Pathol. 2015;8(12):15719–15728.
   PubMed Web of Science ®Google Scholar
• Safaei R, Larson BJ, Cheng TC, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005;4(10):1595–1604.
   PubMed Web of Science ®Google Scholar
• Yin J, Yan X, Yao X, et al. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med. 2012;16(2):337–348.
   PubMed Web of Science ®Google Scholar
• Pink RC, Samuel P, Massa D, et al. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137(1):143–151.
   PubMed Web of Science ®Google Scholar
• Weiner-Gorzel K, Dempsey E, Milewska M, et al. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 2015;4(5):745–758.
   PubMed Web of Science ®Google Scholar
• Zhang FF, Zhu YF, Zhao QN, et al. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Eur J Pharmacol. 2014;738:83–90.
   PubMed Web of Science ®Google Scholar
• Liu C, Yu S, Zinn K, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006;176(3):1375–1385.
   PubMed Web of Science ®Google Scholar
• Clayton A, Mitchell JP, Court J, et al. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007;67(15):7458–7466.
   PubMed Web of Science ®Google Scholar
• Yu S, Liu C, Su K, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007;178(11):6867–6875.
   PubMed Web of Science ®Google Scholar
• Valenti R, Huber V, Iero M, et al. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007;67(7):2912–2915.
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C, Lyons KS, et al. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003;9(14):5113–5119.
   PubMed Web of Science ®Google Scholar
• Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med. 2002;195(10):1303–1316.
   PubMed Web of Science ®Google Scholar
• Meng Y, Kang S, Fishman DA. Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells. Cancer Immunol Immunother. 2005;54(8):807–814.
   PubMed Web of Science ®Google Scholar
• Peng P, Yan Y, Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep. 2011;25(3):749–762.
   PubMed Web of Science ®Google Scholar
• Abrahams VM, Straszewski SL, Kamsteeg M, et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res. 2003;63(17):5573–5581.
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005;92(2):305–311.
   PubMed Web of Science ®Google Scholar
• Rabinowich H, Banks M, Reichert TE, et al. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res. 1996;2(8):1263–1274.
   PubMed Web of Science ®Google Scholar
• Blanchard N, Lankar D, Faure F, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζ Complex. J Immunol. 2002;168(7):3235–3241.
   PubMed Web of Science ®Google Scholar
• Kelleher RJ, Balu-Iyer S, Loyall JL, et al. Extracellular vesicles present in human ovarian tumor microenvironments induce a phosphatidylserine dependent arrest in the T cell signaling cascade. Cancer Immunol Res. 2015;3(11):1269–1278.
   PubMed Web of Science ®Google Scholar
• Koti M, Siu A, Clement I, et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer. 2015;112(7):1215–1222.
   PubMed Web of Science ®Google Scholar
• Bretz NP, Ridinger J, Rupp AK, et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem. 2013;288(51):36691–36702.
   PubMed Web of Science ®Google Scholar
• Atay S, Gercel-Taylor C, Taylor DD. Human trophoblast-derived exosomal fibronectin induces pro-inflammatory IL-1beta production by macrophages. Am J Reprod Immunol. 2011;66(4):259–269.
   PubMed Web of Science ®Google Scholar
• Raposo G, Nijman H, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183(3):1161–1172.
   PubMed Web of Science ®Google Scholar
• Wubbolts R, Leckie RS, Veenhuizen PT, et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem. 2003;278(13):10963–10972.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4(5):594–600.
   PubMed Web of Science ®Google Scholar
• Segura E, Amigorena S, Thery C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis. 2005;35(2):89–93.
   PubMed Web of Science ®Google Scholar
• Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7(3):297–303.
   PubMed Web of Science ®Google Scholar
• Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002;360(9329):295–305.
   PubMed Web of Science ®Google Scholar
• Li QL, Bu N, Yu YC, et al. Exvivo experiments of human ovarian cancer ascites-derived exosomes presented by dendritic cells derived from umbilical cord blood for immunotherapy treatment. Clin Medicine Oncol. 2008;2:461–467.
   PubMedGoogle Scholar
• Rughetti A, Rahimi H, Belleudi F, et al. Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing. Cancer Immunol Res. 2014;2(2):177–186.
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol. 2009;115(1):112–120.
   PubMed Web of Science ®Google Scholar
• Labani-Motlagh A, Israelsson P, Ottander U, et al. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity. Tumour Biol. 2015. doi:10.1007/s13277-015-4313-2
   PubMedGoogle Scholar
• Adams M, Navabi H, Croston D, et al. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine. 2005;23(17–18):2374–2378.
   PubMed Web of Science ®Google Scholar
• Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol. 2004;4(7):512–520.
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Wagner C, Zemann A, et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol. 2004;123(2):371–379.
   PubMed Web of Science ®Google Scholar
• Gelman AE, Zhang J, Choi Y, et al. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172(10):6065–6073.
   PubMed Web of Science ®Google Scholar
• Navabi H, Croston D, Hobot J, et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis. 2005;35(2):149–152.
   PubMed Web of Science ®Google Scholar
• Szajnik M, Derbis M, Lach M, et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy. Gynecol Obstet (Sunnyvale). 2013;Suppl 4:3.
   PubMedGoogle Scholar
• Chaput N, Schartz NE, Andre F, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol. 2004;172(4):2137–2146.
   PubMed Web of Science ®Google Scholar
• Schlienger K, Chu CS, Woo EY, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res. 2003;9(4):1517–1527.
   PubMed Web of Science ®Google Scholar
• Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3(1):9.
   PubMed Web of Science ®Google Scholar
• Altieri SL, Khan ANH, Tomasi TB. Exosomes from plasmacytoma cells as a tumor vaccine. J Immunotherapy. 2004;27(4):282–288.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. PROLOG gynecology and surgery 6th ed.. Washington, DC: American College of Obstetricians and Gynecologists; 2009.
   Google Scholar
• Montagnana M, Danese E, Giudici S, et al. HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem. 2011;55:1–20.
   PubMed Web of Science ®Google Scholar
• Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117(6):1289–1297.
   PubMed Web of Science ®Google Scholar
• Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;5(17):4589–4596.
   PubMed Web of Science ®Google Scholar
• Sarojini S, Tamir A, Lim H, et al. Early detection biomarkers for ovarian cancer. J Oncol. 2012;2012:709049.
   PubMedGoogle Scholar
• Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40–46.
   PubMed Web of Science ®Google Scholar
• Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118(2 Pt 1):280–288.
   PubMed Web of Science ®Google Scholar
• Giusti I, D’Ascenzo S, Dolo V. Microvesicles as potential ovarian cancer biomarkers. Biomed Res Int. 2013;2013:703048.
   PubMedGoogle Scholar
• Im H, Shao H, Park YI, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014;32(5):490–495.
   PubMed Web of Science ®Google Scholar
• Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122–128.
   PubMed Web of Science ®Google Scholar
• Carbotti G, Orengo AM, Mezzanzanica D, et al. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer. 2013;132(11):2597–2605.
   PubMed Web of Science ®Google Scholar
• Escrevente C, Keller S, Altevogt P, et al. Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer. 2011;11:108.
   PubMed Web of Science ®Google Scholar
• Escrevente C, Grammel N, Kandzia S, et al. Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells. Plos One. 2013;8(10):e78631.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy L, Bess JW Jr., Preston AB, et al. HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat Chem Biol. 2009;5(4):244–250.
   PubMed Web of Science ®Google Scholar
• Batista BS, Eng WS, Pilobello KT, et al. Identification of a conserved glycan signature for microvesicles. J Proteome Res. 2011;10(10):4624–4633.
   PubMed Web of Science ®Google Scholar
• Staubach S, Schadewaldt P, Wendel U, et al. Differential glycomics of epithelial membrane glycoproteins from urinary exovesicles reveals shifts toward complex-type N-glycosylation in classical galactosemia. J Proteome Res. 2012;11(2):906–916.
   PubMed Web of Science ®Google Scholar
• Shender VO, Pavlyukov MS, Ziganshin RH, et al. Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteomics. 2014;13(12):3558–3571.
   PubMed Web of Science ®Google Scholar
• Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–364.
   PubMed Web of Science ®Google Scholar
• Brock GC-RE, Hu L, Coticchia C, et al. Liquid biopsy for cancer screening, patient stratification and monitoring. Transl Cancer Res. 2015;4(3):280–290.
   Web of Science ®Google Scholar
• Kuhlmann JD, Rasch J, Wimberger P, et al. microRNA and the pathogenesis of ovarian cancer – a new horizon for molecular diagnostics and treatment? Clin Chem Lab Med. 2012;50(4):601–615.
   PubMed Web of Science ®Google Scholar
• Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011;2:180.
   PubMed Web of Science ®Google Scholar
• Kahlert C, Melo SA, Protopopov A, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014;289(7):3869–3875.
   PubMed Web of Science ®Google Scholar
• Huang X, Yuan T, Tschannen M, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013;14:319.
   PubMed Web of Science ®Google Scholar
• Lunavat TR, Cheng L, Kim DK, et al. Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells – evidence of unique microRNA cargos. RNA Biol. 2015;12(8):810–823.
   PubMed Web of Science ®Google Scholar
• Ji H, Chen M, Greening DW, et al. Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures. Plos One. 2014;9(10):e110314.
   PubMed Web of Science ®Google Scholar
• Liao J, Liu R, Yin L, et al. Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing. Int J Mol Sci. 2014;15(9):15530–15551.
   PubMed Web of Science ®Google Scholar
• Noerholm M, Balaj L, Limperg T, et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012;12:22.
   PubMed Web of Science ®Google Scholar
• Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. Plos One. 2014;9(4):e92921.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids – the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467–477.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67(18):8699–8707.
   PubMed Web of Science ®Google Scholar
• Bagnoli M, De Cecco L, Granata A, et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget. 2011;2(12):1265–1278.
   PubMed Web of Science ®Google Scholar
• Chevillet JR, Kang Q, Ruf IK, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA. 2014;111(41):14888–14893.
   PubMed Web of Science ®Google Scholar
• Rank A, Liebhardt S, Zwirner J, et al. Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Res. 2012;32(5):2009–2014.
   PubMed Web of Science ®Google Scholar
• Cappellesso R, Tinazzi A, Giurici T, et al. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014;122(9):685–693.
   PubMed Web of Science ®Google Scholar
• Zhou J, Gong G, Tan H, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep. 2015;33(6):2915–2923.
   PubMed Web of Science ®Google Scholar
• Zavesky L, Jandakova E, Turyna R, et al. Evaluation of cell-free urine microRNAs expression for the use in diagnosis of ovarian and endometrial cancers. A pilot study. Pathol Oncol Res. 2015;21(4):1027–1035.
   PubMed Web of Science ®Google Scholar
• Meng X, Muller V, Milde-Langosch K, et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016. Mar 2. doi:10.18632/oncotarget.7850. [Epub ahead of print]
   Google Scholar
• Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. J Extracell Vesicles. 2015;4:30087.
   PubMed Web of Science ®Google Scholar
• Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–182.
   PubMed Web of Science ®Google Scholar
• Jeong S, Park J, Pathania D, et al. Integrated magneto-electrochemical sensor for exosome analysis. ACS Nano. 2016;10(2):1802–1809.
   PubMed Web of Science ®Google Scholar